Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET

Company Participants

Ian Karp - Senior Vice President, Investor Relations and Corporate Communications

John Leonard - Chief Executive Officer

David Lebwohl - Chief Medical Officer

Laura Sepp-Lorenzino - Chief Scientific Officer

Glenn Goddard - Chief Financial Officer

Conference Call Participants

Joseph Thome - TD Cowen

Maury Raycroft - Jefferies

Yanan Zhu - Wells Fargo Securities

Dae Gon Ha - Stifel

Liisa Bayko - Evercore ISI

William Pickering - Bernstein

Joon Lee - Truist

Brian Cheng - JPMorgan

Rick Bienkowski - Cantor Fitzgerald

Steve Seedhouse - Raymond James

Silvan Tuerkcan - JMP Securities

Richard Law - Credit Suisse

Operator

Good morning and welcome to the Intellia Therapeutics' First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call. As a reminder, all participants are currently in a listen-only mode.

I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

Ian Karp

Thank you, operator, and good morning, everyone. Welcome to Intellia Therapeutics first quarter 2023 earnings call. Earlier this morning, Intellia issued a press release outlining the Company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors & Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a replay will be archived on the Company's website.

At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law.

Joining me from Intellia are Dr. John Leonard, Chief Executive Officer; Dr. David Lebwohl, Chief Medical Officer; and Glenn Goddard, Chief Financial Officer. John will begin with an overview of recent business highlights. David will provide an update on our clinical programs and Glenn will review financial results for the first quarter 2023 before we open up the call for Q&A at which time Dr. Laura Sepp-Lorenzino, our Chief Scientific Officer will also be available.